Legal Disclaimer

The content and information provided within this site is for informational and educational purposes only. Consult a doctor before pursuing any form of therapy, including Hyperbaric Oxygen Therapy. The Information provided within this site is not to be considered Medical Advice. In Full Support of the F.D.A., Hyperbaric Oxygen Therapy is considered Investigational, Experimental, or Off Label.

Please consult with your Treating Medical Physician

Neurology 1997 Dec;49(6):1621-30
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study

The North America ALS/IGF-I Study Group.

Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA.

Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.

Recombinant human insulin-like growth factor-I slowed the progression of functional impairment and the decline in health-related quality of life in patients with ALS with no medically important adverse effects.

Printed with Permission